tradingkey.logo

BUZZ-Bluebird bio falls on discounted take private deal with Carlyle, SK Capital

ReutersFeb 21, 2025 1:22 PM

Shares of gene therapy maker bluebird bio BLUE.O fall 38.6% to $4.32 premarket

Co says it would be taken private by Carlyle CG.O and SK Capital Partners

BLUE stockholders will receive $3/shr in cash, implying an equity value of around $29.2 mln

The offer is at an over 57% discount from the stock's last close of $7.04

Investment firms have also offered additional $6.84/shr, contingent upon achieving certain sales milestones, which represents a payment of about $66.5 mln

BLUE fell 69.8% in 2024

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI